AKANDA CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.34 USD | +2.63% |
|
-2.50% | -86.72% |
| 05-28 | Top Premarket Decliners | MT |
| 05-24 | Top Premarket Gainers | MT |
| Sales 2022 | 2.62 207.17 | Sales 2023 | 2.16 170.82 | Capitalization | 1.77M 140M |
|---|---|---|---|---|---|
| Net income 2022 | -11M -870M | Net income 2023 | -32M -2.53B | EV / Sales 2022 | 1,845,573 x |
| Net Debt 2022 | 3.41 269.45 | Net Debt 2023 | 3.92 309.69 | EV / Sales 2023 | 820,820 x |
| P/E ratio 2022 |
-0.38
x | P/E ratio 2023 |
-0.06
x | Employees | 46 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 97.82% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +2.63% | ||
| 1 week | -2.50% | ||
| Current month | -10.00% | ||
| 1 month | -37.10% | ||
| 3 months | -72.01% | ||
| 6 months | -85.94% | ||
| Current year | -86.72% |
1 week
2.16
2.88
1 month
2.125.66
Current year
2.1228.40
1 year
2.1242.00
3 years
2.1212 400.00
5 years
2.1212 400.00
10 years
2.1212 400.00
| Managers | Title | Age | Since |
|---|---|---|---|
Katharyn Field
CEO | Chief Executive Officer | 41 | 22/06/22 |
Charn Deol
DFI | Director of Finance/CFO | 56 | 12-10 |
Matt Chesler
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jay Dhaliwal
BRD | Director/Board Member | 35 | 22/06/22 |
Katharyn Field
CEO | Chief Executive Officer | 41 | 22/06/22 |
David Jenkins
BRD | Director/Board Member | 43 | 12/02/23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/06/24 | 2.34 | +2.63% | 1,400,014 |
| 20/06/24 | 2.28 | +2.24% | 925,852 |
| 18/06/24 | 2.23 | -1.76% | 151,206 |
| 17/06/24 | 2.27 | -5.42% | 92,514 |
| 14/06/24 | 2.4 | -4.76% | 248,821 |
Delayed Quote Nasdaq, June 21, 2024 at 09:00 pm
More quotes
Akanda Corp. is an international medical cannabis and wellness platform company. The Companyâs portfolio includes Canmart Ltd. (CanMart), a United Kingdom-based fully licensed pharmaceutical importer and distributor which supplies pharmacies and clinics within the United Kingdom. Canmart is a licensed importer and distributor of CBD Extraction for Medicinal Purposes (CBPMs) in the United Kingdom. CanMart holds a controlled drug license issued by the Home Office to possess and supply CBPMs in the United Kingdom. The Company's seed-to-patient supply chain also includes partnerships Cellen Life Sciences' Leva Clinic, a fully digital pain clinic in the United Kingdom. The Company also develops a Canadian farming property in British Columbia, including farming land and related operations and licenses. The Company also focuses on developing tetrahydrocannabinol (THC) and cannabinoid (CBD) facilities at this site.
| 1st Jan change | Capi. | |
|---|---|---|
| -86.72% | 4.49M | |
| +10.70% | 216M | |
| -8.25% | 190M | |
| +23.26% | 160M | |
| +300.00% | 121M | |
| +25.87% | 114M | |
| -42.86% | 96.48M | |
| +69.68% | 95.27M | |
| -57.11% | 90.59M | |
| -15.38% | 73.41M |
- Stock Market
- Equities
- AKAN Stock
